首页> 外文OA文献 >Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

【2h】

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

机译：固定剂量组合Bictegravir，Emtricitabine和替诺福韦alafenamide与含Dolutegravir的初始治疗方案进行HIV-1感染：第144周的两项随机，双盲，多期，阶段3，非劣级试验结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Chloe Orkin; Edwin DeJesus; Paul E Sax; Jose R Arribas; Samir K Gupta; Claudia Martorell; Jeffrey L Stephens; Hans-Jurgen Stellbrink; David Wohl; Franco Maggiolo; Melanie A Thompson; Daniel Podzamczer; Debbie Hagins; Jason A Flamm; Cynthia Brinson; Amanda Clarke; Hailin Huang; Rima Acosta; Diana M Brainard; Sean E Collins; Hal Martin;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial [J] . Sax Paul E., Pozniak Anton, Montes M. Luisa, The Lancet . 2017,第10107期

机译：Coformulated Bictegravir，Emtricitabine和Tenofovir Alafenamide与eMtrickabine和替汀·韦昔洛酰胺，用于初步治疗HIV-1感染（GS-US-380-1490）：随机，双盲，多期，第3期，非劣级试验
2. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial [J] . Gallant Joel, Lazzarin Adriano, Mills Anthony, The Lancet . 2017,第10107期

机译：Bictegravir，Emtricicabine和Tenofovir Alafenainide对DoluteGravir，Abacavir和Lamivudine进行HIV-1感染的初始治疗（GS-US-380-1489）：双盲，多期，第3期，随机控制的非劣级试验
3. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (vol 385, pg 2606, 2015) [J] . Sax P. E., Wohl D., Yin M. T. The Lancet . 2016,第10030期

机译：替诺福韦alafenamide与替诺福韦富马酸替索洛韦联合elvitegravir，cobicistat和恩曲他滨联合配制，用于HIV-1感染的初始治疗：两项随机，双盲，3期，非劣效性试验（第385卷，第2606页，2015年）
4. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized Double-Blind Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir Emtricitabine and Tenofovir Alafenamide versus Co-formulated Abacavir Dolutegravir and Lamivudine [O] . David Wohl, Amanda Clarke, Franco Maggiolo, -1

机译：在联合配制的比格韦恩曲他滨和替诺福韦阿拉芬酰胺与联合配制的阿巴卡韦多洛格韦和拉米夫定联合治疗的成人HIV随机双盲III期非劣效性试验参与者中患者报告的症状超过48周
5. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial [O] . David A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, 2019

机译：Bictegravir与Emtricitabine和Tenofovir Alafenainide相结合，与Dolutegravir，Abacavir和Lamivudine进行HIV-1感染的初始治疗：第96周的随机，双盲，多期，第3期，非劣级试验结果

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

著录项

相似文献

相关主题

期刊订阅